Effects of prostaglandins F2 alpha, A2, and their esters in glaucomatous monkey eyes

The effect of prostaglandin (PG) F2 alpha-isopropyl ester (IE), PGA2, or PGA2-IE on intraocular pressure (IOP) was tested in eight cynomolgus monkey eyes with argon laser-induced glaucoma. Dose-response testing and baseline IOP measurements were done. For multiple dose testing, 5 micrograms in 25 mi...

Full description

Saved in:
Bibliographic Details
Published inInvestigative ophthalmology & visual science Vol. 31; no. 11; pp. 2466 - 2470
Main Authors Wang, RF, Camras, CB, Lee, PY, Podos, SM, Bito, LZ
Format Journal Article
LanguageEnglish
Published Rockville, MD ARVO 01.11.1990
Association for Research in Vision and Ophtalmology
Subjects
Administration, Topical
Animals
Biological and medical sciences
Dinoprost - analogs & derivatives
Dinoprost - therapeutic use
Dinoprost - toxicity
Disease Models, Animal
Dose-Response Relationship, Drug
Eye
Glaucoma - drug therapy
Intraocular Pressure - drug effects
Macaca fascicularis
Medical sciences
Pharmacology. Drug treatments
Prostaglandins A - therapeutic use
Prostaglandins A - toxicity
Glaucoma
Toxicity
Arachidonic acid derivatives
Monkey
Prostaglandin A2
Prostaglandin F2α
Dose activity relation
Multiple dose
Ester
Vertebrata
Chemotherapy
Eye disease
Experimental disease
Mammalia
Treatment
Animal
Primates
Intraocular pressure
Online AccessGet full text

Cover

More Information
Summary:The effect of prostaglandin (PG) F2 alpha-isopropyl ester (IE), PGA2, or PGA2-IE on intraocular pressure (IOP) was tested in eight cynomolgus monkey eyes with argon laser-induced glaucoma. Dose-response testing and baseline IOP measurements were done. For multiple dose testing, 5 micrograms in 25 microliters (0.02%) of each PG was topically applied twice daily for 5 days. The IOP was measured at 30- or 60-minute intervals for 6 hours after the morning dose each day. A significant (P less than 0.05) reduction of IOP peaked at 5-9 mm Hg below baseline values on the 5th day of treatment for each PG. The ocular hypotensive effect of these PGs progressively became more pronounced during the course of twice-daily dosing, with a significant reduction maintained at least 17 hours after some doses. No more than trace aqueous flare and no cells were observed in any eye during the course of treatment. These findings demonstrate that PGs other than F2 alpha are potent ocular hypotensive agents in primates.
ISSN:0146-0404
1552-5783